Around the Practice: Advanced Urothelial Carcinoma

Neeraj Agarwal, MD, leads the discussion on the typical patient presentation and major risk factors for urothelial cancer.

Bladder cancer experts discuss the importance of detecting early signs and symptoms leading to the diagnosis of advanced urothelial cancer.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, share their approach to frontline therapy for patients with advanced urothelial carcinoma and consider the impact of cisplatin eligibility.

Experts in bladder cancer comment on the role of PD-L1 testing in the frontline setting for advanced urothelial cancer and its impact on the use of up-front carboplatin or immunotherapy.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, provide insight on how they approach the patient selection of maintenance therapy in advanced urothelial carcinoma.

Thomas Powles, MBBS, MRCP, MD, reviews data and results from the phase 3 JAVELIN Bladder 100 trial for patients with locally advanced or metastatic urothelial cancer.

Petros Grivas, MD, PhD, presents the case of a 78-year-old man with PD-L1+ metastatic urothelial carcinoma, and the panelists share insight on their treatment approach for the given patient.

Experts in bladder cancer discuss when it’s appropriate to use avelumab maintenance therapy both with and without progression of disease in advanced urothelial cancer.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, comment on the role of biomarker testing and its impact on the patient selection and approach to treatment for advanced urothelial carcinoma.

Guru P. Sonpavde, MD, leads the discussion on the use of adjuvant nivolumab in metastatic urothelial carcinoma and the impact on the subsequent use of immune checkpoint inhibitors in recurrent disease.

Thomas Powles, MBBS, MRCP, MD, leads the discussion on selecting chemotherapy vs immune checkpoint inhibitors in the adjuvant setting for a patient who has metastases in urothelial carcinoma as well as approaching therapy for variant histology.

CancerNetwork® recap of an Around the Practice event with Neeraj Agarwal, MD, Petros Grivas, MD, PhD, Guru Sonpavde, MD, Thomas Powles, MBBS, MD, MRCP